



(51) International Patent Classification:

C07D 401/06 (2006.01) C07D 407/14 (2006.01)
C07D 401/14 (2006.01) C07D 413/06 (2006.01)
C07D 413/14 (2006.01) C07D 471/04 (2006.01)
C07D 403/14 (2006.01)

(21) International Application Number:

PCT/IB2013/060682

(22) International Filing Date:

5 December 2013 (05.12.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/740,596 21 December 2012 (21.12.2012) US

(71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street,
New York, NY 10017 (US).

(72) Inventors: EDWARDS, Martin Paul; c/o Pfizer Inc.,
10555 Science Center Drive, San Diego, California 92121
(US). KUMPF, Robert Arnold; 3280 Avenida Anacapa,
Carlsbad, California 92009 (US). KUNG, Pei-Pei; 5504
Shannon Ridge Lane, San Diego, California 92130 (US).
MCALPINE, Indrawan James; 7190 Calabria Court,
Unit C, San Diego, California 92122 (US). NINKOVIC,
Sacha; 8902 Nottingham Place, La Jolla, California 92037
(US). RUI, Eugene Yuanjin; 11254 Caminito Corriente,

San Diego, California 92128 (US). SUTTON, Scott
Channing; 11660 Weatherwood Place, San Diego, Califor-
nia 92131 (US). TATLOCK, John Howard; 10220 Cam-
ino San Thomas, San Diego, California 92127 (US).
WYTHES, Martin James; c/o Pfizer Inc., 10555 Science
Center Drive, San Diego, California 92121 (US).
ZEHNDER, Luke Raymond; 4653 Rainier Avenue, San
Diego, California 92120 (US).


(74) Agent: KLEIMAN, Gabriel L.; Pfizer Inc., 235 East 42nd
Street, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

[Continued on next page]

(54) Title: ARYL AND HETEROARYL FUSED LACTAMS



(57) Abstract: This invention relates to compounds of general Formula (I) in which R¹, R², U, V, L, M, R⁵, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.



TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Declarations under Rule 4.17:

— as to the identity of the inventor (Rule 4.17(i))

Published:

— with international search report (Art. 21(3))